Key clinical point: Among patients with relapsing-remitting MS, depression increases the likelihood of having worse neurologic function 1 year later.

Major finding: In an adjusted model, MS patients with depression were more likely to have a 20% worsening in at least one neurologic performance measure at year 1, compared with MS patients without depression (OR, 1.31).

Study details: An analysis of data from approximately 2,400 patients in MS PATHS.

Disclosures: The presenting author had no disclosures. Two coauthors have consulted for and received research support from pharmaceutical companies. MS PATHS is supported by Biogen.